NaglaFawzyAbdel KarimMD

Professor, Internal Medicine, Division of Hematology/Oncology-Augusta University-Georgia Cancer Center

Dr. Abdel Karim is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
8081 Innovation Park Dr
Fairfax, VA 22031
Phone+1 571-472-4724

Fax+1 571-472-0241

University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
Cleveland Clinic Foundation/Fairview HospitalResidency, Internal Medicine, 2003 - 2006
Cairo University School of MedicineClass of 1993

PubMed

Clinical insights: five-year follow-up of KEYNOTE-189 trial outcomes and more.
Bobby Se, Athar Eysa, Nagla Karim
Translational Lung Cancer Research. 2024-08-31
1 citations
Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Jonathan N Priantti, Maysa Vilbert, Francisco Cezar Aquino de Moraes, Thiago Madeira, Evair Moisés de Lima Santiago
Cancers. 2024-07-22
4 citations
Metastatic Malignant Peripheral Nerve Sheath Tumor (MPNST) in Neurofibromatosis Type 1: Challenges in Diagnosis and Management.
Steven Pulliam, Kiran Madwani, Ashley D Fox, Nadia El-Hachoum, Asad Ullah
Cureus. 2022-06-01

Lectures

Phase I trial of chloroquine (CQ)/hydroxychloroquine (HCQ) in combination with carboplatin-gemcitabine (CG) in patients with advanced solid tumors.
2019 ASCO Annual Meeting - 6/1/2019
Correlation between K-RAS mutant subsets, TP53 mutation, and PD-L1 status in non-small cell lung cancer (NSCLC).
2019 ASCO Annual Meeting - 6/1/2019